Antibody drug discovery and development company Sanyou Biopharmaceuticals said on Tuesday that it was recognised with the '2025 Best Customer Satisfaction CRO Award' at the 7th China Bio Innovation Expo awards ceremony, which took place in Suzhou, China on 1 August.
The award recognised the company's deep expertise and outstanding performance in the field of preclinical research for new drug development.
According to Sanyou Bio, this award reflects the industry's high regard for the company's overall capabilities and also serves as strong validation of its commitment to driving innovation in biopharmaceutical R&D.
The company stated: "Winning the '2025 Best Customer Satisfaction CRO Award' is a testament to Sanyou Bio's past achievements and a powerful motivation for future growth. We sincerely thank our peers and partners across the industry for their continued trust and support. Sanyou Bio will remain true to its mission and continue forging ahead, striving for new milestones on the path of biopharmaceutical innovation."
Novartis reports positive Phase III results for ianalumab in Sjögren's disease
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
Akeso doses first patient in Phase III Ivonescimab small cell lung cancer trial
Polymer Factory-led study advances nanocarrier-based drug delivery for aggressive cancers
RemeGen receives FDA approval to advance RC148 into Phase II trials for solid tumours
Spinogenix reports positive first cohort results from Phase 2a trial in Alzheimer's disease
Sebela Pharmaceuticals completes tegoprazan Phase 3 TRIUMpH programme in GERD with positive results
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Sanofi completes USD470m acquisition of Vigil Neuroscience
Sanyou Bio wins 'Best Customer Satisfaction CRO Award'
Kowa begins Phase 3 safety trial of Nicox's NCX 470 in Japan, triggering EUR2m milestone
MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241